TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01727661

Intervention type: BEHAVIORAL
Intervention: exercise testing with near-infrared spectroscopy
Description: subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.

Intervention type: BEHAVIORAL
Intervention: exercise testing with near-infrared spectroscopy
Description: subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.

Intervention type: BEHAVIORAL
Intervention: lung function testing
Description: spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds.

Intervention type: BEHAVIORAL
Intervention: lung function testing
Description: spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds.

Intervention type: BEHAVIORAL
Intervention: quality of life
Description: assessing quality of life using short-forum 36 (questionnaire)

Intervention type: BEHAVIORAL
Intervention: quality of life
Description: assessing quality of life using short-forum 36 (questionnaire)
Study: NCT03516097

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured school based intervention
Description: Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured school based intervention
Description: Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile app usage
Description: The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile app usage
Description: The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
Study: NCT02661633

Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.

Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.

Intervention type: DEVICE
Intervention: Advanced MRI Neuroimaging
Description: Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
Study: NCT03713320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Description: At least weekly doses of cobomarsen (282 mg) throughout study treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: Daily doses of vorinostat throughout study treatment period
Study: NCT00823836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropinirole PR/XR
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole PR/XR
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropinirole IR
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
Study: NCT04454099

Intervention type: DIAGNOSTIC_TEST
Intervention: 4 kind of FOBT and colonoscopy with pathological examination
Description: Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
Study: NCT00776022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride 10 mg tablet
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
Study: NCT01945398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SHAM
Description: Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
Study: NCT03874936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24mg Solution for Injection
Description: Administrated i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 24mg Solution for Injection
Description: Administrated i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution for Injection
Description: administrated i.v.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution for Injection
Description: administrated i.v.
Study: NCT02868671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Study: NCT04135508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1406
Description: 40mg/0.8ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: 40mg/0.8ml
Study: NCT00924222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sedation with sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sedation with sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation on intensive care unit with propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation on intensive care unit with propofol
Study: NCT02900235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995
Study: NCT03537235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libramed

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04226092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPSkin Barrier Pro
Description: This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPSkin Barrier Pro
Description: This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquaflux AF200
Description: This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquaflux AF200
Description: This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
Study: NCT01993277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexalin Brain Stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fischer Wallace Stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: David Delight Stimulator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Therapy
Study: NCT00813982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A Experimental Contact Lens
Description: Experimental spherical, silicone hydrogel soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon A Commercial Contact Lens
Description: Commercially marketed spherical, silicone hydrogel soft contact lens
Study: NCT03338647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEB
Description: Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: High precision radiation therapy to the liver tumor(s)
Study: NCT01781832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI-Derived Shear Wave Velocities
Description: An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
Study: NCT04171349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine
Description: Vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: Vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Vial
Study: NCT02719743

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
Description: All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
Study: NCT02990468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: Subcutaneous injection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will receive standard dose intensity modulated radiation therapy (IMRT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered per institution's standard of care practice.
Study: NCT00085566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Study: NCT04092452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 400 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 45 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647
Description: 400 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03672942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
Study: NCT04430166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: 200mg / intravenous drip, once every three weeks
Study: NCT03439618

Intervention type: OTHER
Group type: OTHER
Intervention: time-restricted feeding
Description: At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.

Intervention type: OTHER
Group type: OTHER
Intervention: continuous feeding
Description: At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
Study: NCT01912989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
Study: NCT01404897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: 3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
Study: NCT00968357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCV-07
Description: SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy.
Study: NCT00565890

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: thyroxine
Description: thyroxine at the dose of 5 μg/kg-wt /day
Study: NCT00004088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT03653247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor subcutaneous injection will be administered prior to apheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan IV infusion will be administered as myeloablative conditioning therapy.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIVV003
Description: BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
Study: NCT02970097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20ml bolus of 0.5% ropivicaine
Description: local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml of 0.5% ropivicaine
Description: local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2 mg of medication given intravenously before nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 50-100 mcg of medication given intravenously before nerve block
Study: NCT03763149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI188
Description: The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days.